Objective: Uric acid is known to be elevated in preeclampsia. We sought to determine if uric acid levels on admission correlate with the length of expectant management in preterm patients with preeclampsia.
Introduction
Uric acid levels are elevated in preeclampsiaFan association that has been noted since at least the late 1800s. 1 While the association between uric acid levels and preeclampsia has been established for over a century, the reason for the increase is not known. The two main competing explanations are (a) decreased renal excretion, due to abnormal renal function and (b) increased production, secondary to increased tissue breakdown, acidosis and/or increased activity of the enzyme xanthine oxidase/ dehydrogenase. 2 Elevations in uric acid levels are not part of the diagnostic criteria for preeclampsia but have been shown to precede the development of hypertension and proteinuria. 3 Literature on the usefulness of uric acid in the prediction of preeclampsia itself or of the complications of preeclampsia has been conflicting. Some studies have suggested that it is suboptimal as a predictor of preeclampsia; [4] [5] [6] however, uric acid does appear to correlate with adverse maternal and neonatal outcomes. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Current management of the patient with mild preeclampsia who is preterm (that is, <37 weeks gestation) often includes hospital admission, the administration of steroids to promote fetal lung maturity (if <34 weeks), and ongoing maternal and fetal surveillance. Patients with severe preeclampsia are typically delivered by 34 weeks. If the patient is stable and testing is reassuring, expectant management is attempted with the effort to prolong the pregnancy to a more advanced gestational age, whereby the fetus will be less likely to suffer from sequelae of prematurity. 18 In this study, we investigated whether uric acid level at the time of admission correlated with the length of expectant management in patients with preeclampsia.
Methods
The study was approved by the Institutional Review Board at Tufts Medical Center. Billing records were used to identify all cases of preeclampsia at Tufts Medical Center from January 2005 through December 2007. Consecutive cases where patients were admitted with the diagnosis of preeclampsia and expectant management was attempted were identified. The diagnosis of preeclampsia was based on standard criteria: the presence of elevated blood pressure (two readings of X140 mm Hg systolic or X90 mm Hg diastolic, 6 h apart), and X300 mg protein on a 24-h urine protein collection or persistent proteinuria (>1 þ ) on a urine dipstick.) The usual management at Tufts Medical Center is to deliver patients with mild preeclampsia at 37 weeks and severe preeclampsia at 34 weeks; therefore, patients with preeclampsia and a gestational age >37 weeks were not included in the study. Twin pregnancies were not included given the alterations in uric acid levels present in multiple gestations. Patients who were transferred back to their referring hospital before delivery were also excluded. Patients who were admitted at or after 36 0/7 weeks and delivered at 37 0/7 were also excluded, as they would be unable to attain >1 week of expectant management based on our standard approach of delivery at 37 0/7 weeks for preeclamptic patients. All patients were expectantly managed in the hospital; outpatient management of preeclampsia is not practiced at our institution.
Data collected on patients included their age, race, gravidity, parity, gestational age at admission and delivery, admission blood pressure, height and weight. Laboratory values were collected at the time of admission and delivery including uric acid, hematocrit, platelet count, aspartate aminotransferase, alanine aminotransferase, creatinine, lactate dehydrogenase and 24-h urine values. Any maternal complications (for example, diabetes, chronic hypertension, etc.) or medication use was noted. Delivery information included infant gender and birthweight.
Correlation between uric acid at admission and length in days of expectant management was assessed. The initial calculation was a direct assessment of the correlation between uric acid on admission in mg dl -1 and the length of expectant management (that is, days between admission and delivery). Patients were then further separated into seven groups based on admission uric acid level (p3.0 mg dl -1 , 3.1 to 4.0, 4.1 to 5.0, 5.1 to 6.0, 6.1 to 7.0, 7.1 to 8.0 and X8.1 mg dl -1 ). Probability of expectant management for >1 week was calculated. P-value for trend was used to test consistency of increasing uric acid levels with decreasing probability of expectant management.
For clinical application, patients were further separated into three groups based on their uric acid levels at admission: low (p4.0 mg dl -1 ), medium (4.1 to 6.0) and highly elevated (X6.1). Demographic and clinical characteristics were calculated for the three groups defined by uric acid levels. To estimate differences between the groups, the one-way analysis of variance or Kruskal-Wallace test was used for continuous variables as appropriate, and the Fisher's exact test was used for categorical variables. Length of expectant management was calculated as the length of time from admission to our medical center until delivery. The probability of expectant management for >1 week was compared using the relative risk (RR) of this outcome in the low and medium uric acid groups with that for the high uric acid group as the referent. Mantel-Haenszel w 2 values were used to construct 95% confidence intervals (CIs) around the RR. 19 To determine the consistency of increasing uric acid levels with decreasing length of expectant management, the P-value for trend was used. 20 The days of expectant management was linearly regressed on uric acid levels at preeclampsia diagnosis. A correlation coefficient, r, was calculated in order to determine the amount of variability of expectant management days that is attributable to uric acid levels at diagnosis. 20 Kaplan-Meier survival analysis was used to compare time of expectant management among the three groups defined by clinical cut points (p4.0, 4.1 to 6.0 and X6.1 mg dl -1 ). A ROC (receiver operating characteristic) curve was generated to summarize the accuracy of uric acid at admission to predict <7 days of expectant management. Sensitivity, specificity, positive predictive values and negative predictive values were calculated for the above clinical cut points and those cut points corresponding to maximal sensitivity and specificity on the ROC curve.
Results
Four hundred seventy-one charts were reviewed. Of these, 190 met inclusion criteria (Figure 1 ). In the entire study population, the mean age was 30.1 years (range: 17 to 44 years). Median gravidity was 2 (range: 1 to 11) and parity 0 (range: 0 to 5). Median gestational age at admission was 32 weeks and 1 day. Median Uric acid in expectantly managed preeclampsia AC Urato et al gestational age at delivery was 33 weeks and 1 day. Fifty-five patients (28.9%) were managed expectantly for >1 week. Table 1 describes the characteristics of the groups based on admission uric acid level. Figure 2 shows the correlation between admission uric acid level and the length of expectant management. Table 2 indicates that when uric acid levels were categorized with narrow ranges, all women with uric acid levels of <3.0 mg dl -1 had expectant management length of >7 days. There were no women with expectant management lengths >7 days whose uric acid levels were >8.1 mg dl -1 (Table 2 ) (P-value for trend <0.0001).
To provide more clinically relevant cutoffs, uric acid levels at preeclampsia diagnosis were then further categorized as p4.0 mg dl -1 (low uric acid level), 4.1 to 6.0 mg dl -1 (medium) and X6.1 mg dl -1 (high) ( Table 3 ). Relative to women with high uric acid levels at diagnosis, we observed a sevenfold higher success rate of extending expectant management for >1 week among women with low uric acid levels (RR: 7.0; 95% CI: 3.34 to 14.68). Women with medium uric acid levels at diagnosis also had a higher success rate relative to women with high uric acid levels (RR: 2.81; 95% CI: 1.32 to 5.96) (P-value for trend <0.0001). Kaplan-Meier analysis of time to delivery indicates a significantly increased probability of delivery over time with higher uric acid levels on admission (Figure 3) . The ROC curve indicates that uric acid levels on admission in the range of 5 to 6 mg dl -1 are associated with the highest sensitivity and specificity in predicting 1 week of expectant management (Figure 4) . Sensitivity for these cut points in predicting <1 week of expectant management ranged from 44.2 to 78.3% and specificity ranged from 47.5 to 82.0% (Table 4) . 
Discussion
In this study, we found that in patients who are admitted with the diagnosis of preeclampsia, admission uric acid level is correlated with the length of expectant management. Pregnancy prolongation for >1 week is significantly more likely in patients with low (p4.0 mg dl -1 ) and medium (4.1 to 6.0 mg dl -1 ) uric acid levels at time of admission compared with those patients with high uric acid levels (>6.0 mg dl -1 ). The admission uric acid level was inversely associated with the length of expectant managementFpatients with higher uric acid levels on admission were more likely to be delivered within 1 week in comparison to patients with lower uric acid levels. Uric acid in expectantly managed preeclampsia. Our findings are consistent with a large number of studies that have shown uric acid levels to be associated with maternal and fetal complications or disease severity in preeclampsia. As early as 1956, Lancet and Fisher 7 reported on the value of blood uric acid levels in toxemia of pregnancy. Subsequent studies confirmed these findings. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Wakwe and Abudu showed elevated uric acid to be associated with eclampsia 12 while Roberts et al. 14 showed that the risk of preterm birth, and small-for-gestational-age infants increased with increasing uric acid. The severity of retinopathy in preeclamptic patients has also been found to be directly related to serum uric acid level. 16 It is possible that admission uric acid is associated with the length of expectant management because the uric acid is a marker of overall disease severity. For example, the elevated uric acid levels may be due to decreased renal excretion. Patients with more severe preeclampsia are more likely to have worsened end-organ function of the kidneys. This worsened renal function is exhibited as a higher uric acid level and these patients would be expected to have a shorter length of expectant management due to increased disease severity. On the other hand, the elevated uric acid levels may be due to increased production from cell death due to placental or peripheral ischemia or necrosis. Consequently, the patients with higher uric acid levels are those with more cellular death. These patients would also be expected to have a shorter length of expectant management before requiring delivery.
It is also possible that uric acid is more than just a marker of severity. It may, in fact, contribute directly to the disease itself. Using animal data, as well as studies in nonpregnant humans, Kang et al. 21 and Bainbridge and Roberts 2 have argued that uric acid itself acts as a pathogenic factor in preeclampsia, with adverse effects upon both the placenta and maternal vasculature. In this model, preeclamptic patients with high uric acid levels on admission are those with the greatest degree of ongoing injury to the placenta and vasculature from the uric acid, the result of which is a more rapid worsening of maternal or fetal condition resulting in earlier delivery.
Some of the limitations of our study include its retrospective nature and the limitations inherent in chart reviews. Also, a possibly significant confounding factor for the study would be if patients with higher uric acid levels were delivered sooner because of their higher levels. We feel that this is not likely to have played a significant role since uric acid elevations are not used as a criterion for delivery at our center. Also, while our study does demonstrate that uric acid at the time of admission is correlated with the length of expectant management, it does not prove causation and it is likely that there is an interplay of several factors that ultimately impact on the length of expectant management for these pregnancies.
While our results indicate that admission uric acid level is clearly associated with the length of expectant management in preeclampsia, it is neither sensitive nor specific enough to be an optimal 'stand alone' screening test. Given the heterogeneous nature of preeclampsia, with its large variety of clinical presentations and outcomes, it is likely that uric acid levels will be most useful when combined with other clinical and laboratory findings to develop a more complete picture of the degree of severity of the patient's condition and the likelihood of extended expectant management.
In conclusion, our study found that in preeclamptic patients, the uric acid level at the time of admission was associated with the length of expectant management. This information can be used clinically to help guide management and for counseling of the patient regarding prognosis. Further investigation into how uric acid levels at admission could be integrated with other clinical information to optimize prediction of maternal and fetal outcomes is warranted.
